359 related articles for article (PubMed ID: 16937518)
1. Cyclooxygenases in hepatocellular carcinoma.
Cervello M; Montalto G
World J Gastroenterol; 2006 Aug; 12(32):5113-21. PubMed ID: 16937518
[TBL] [Abstract][Full Text] [Related]
2. The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells.
Lampiasi N; Foderà D; D'Alessandro N; Cusimano A; Azzolina A; Tripodo C; Florena AM; Minervini MI; Notarbartolo M; Montalto G; Cervello M
Int J Mol Med; 2006 Feb; 17(2):245-52. PubMed ID: 16391822
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation.
Koga H; Sakisaka S; Ohishi M; Kawaguchi T; Taniguchi E; Sasatomi K; Harada M; Kusaba T; Tanaka M; Kimura R; Nakashima Y; Nakashima O; Kojiro M; Kurohiji T; Sata M
Hepatology; 1999 Mar; 29(3):688-96. PubMed ID: 10051469
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway.
Cusimano A; Foderà D; D'Alessandro N; Lampiasi N; Azzolina A; Montalto G; Cervello M
Cancer Biol Ther; 2007 Sep; 6(9):1461-8. PubMed ID: 18424914
[TBL] [Abstract][Full Text] [Related]
5. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
Bae SH; Jung ES; Park YM; Kim BS; Kim BK; Kim DG; Ryu WS
Clin Cancer Res; 2001 May; 7(5):1410-8. PubMed ID: 11350912
[TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2: a novel target for cancer chemotherapy?
Dempke W; Rie C; Grothey A; Schmoll HJ
J Cancer Res Clin Oncol; 2001 Jul; 127(7):411-7. PubMed ID: 11469677
[TBL] [Abstract][Full Text] [Related]
7. The significance of cyclooxygenase-2 expression in human hepatocellular carcinoma.
Chi-Man Tang T; Tung-Ping Poon R; Fan ST
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S311-6. PubMed ID: 16507400
[TBL] [Abstract][Full Text] [Related]
8. Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells.
Abiru S; Nakao K; Ichikawa T; Migita K; Shigeno M; Sakamoto M; Ishikawa H; Hamasaki K; Nakata K; Eguchi K
Hepatology; 2002 May; 35(5):1117-24. PubMed ID: 11981761
[TBL] [Abstract][Full Text] [Related]
9. Cyclooxygenase-2 (COX-2)--a therapeutic target in liver cancer?
Breinig M; Schirmacher P; Kern MA
Curr Pharm Des; 2007; 13(32):3305-15. PubMed ID: 18045183
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
11. Regulation of 15-hydroxyprostaglandin dehydrogenase expression in hepatocellular carcinoma.
Castro-Sánchez L; Agra N; Llorente Izquierdo C; Motiño O; Casado M; Boscá L; Martín-Sanz P
Int J Biochem Cell Biol; 2013 Nov; 45(11):2501-11. PubMed ID: 23954207
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 in hepatocellular carcinoma.
Wu T
Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
[TBL] [Abstract][Full Text] [Related]
13. Dual acting anti-inflammatory drugs: a reappraisal.
Bertolini A; Ottani A; Sandrini M
Pharmacol Res; 2001 Dec; 44(6):437-50. PubMed ID: 11735348
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
15. Celecoxib: a specific COX-2 inhibitor with anticancer properties.
Koki AT; Masferrer JL
Cancer Control; 2002; 9(2 Suppl):28-35. PubMed ID: 11965228
[TBL] [Abstract][Full Text] [Related]
16. [Significance of cyclooxygenase-2 as a chemotherapeutic target in hepatocellular carcinoma].
Kern MA; Schirmacher P; Breinig M
Verh Dtsch Ges Pathol; 2007; 91():257-68. PubMed ID: 18314623
[TBL] [Abstract][Full Text] [Related]
17. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma.
Cheng AS; Chan HL; To KF; Leung WK; Chan KK; Liew CT; Sung JJ
Int J Oncol; 2004 Apr; 24(4):853-60. PubMed ID: 15010822
[TBL] [Abstract][Full Text] [Related]
18. Correlation between expression of cyclooxygenase-2 and the presence of inflammatory cells in human primary hepatocellular carcinoma: possible role in tumor promotion and angiogenesis.
Cervello M; Foderàa D; Florena AM; Soresi M; Tripodo C; D'Alessandro N; Montalto G
World J Gastroenterol; 2005 Aug; 11(30):4638-43. PubMed ID: 16094702
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal anti-inflammatory drugs in prevention of gastric cancer.
Dai Y; Wang WH
World J Gastroenterol; 2006 May; 12(18):2884-9. PubMed ID: 16718813
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma.
Kondo M; Yamamoto H; Nagano H; Okami J; Ito Y; Shimizu J; Eguchi H; Miyamoto A; Dono K; Umeshita K; Matsuura N; Wakasa K; Nakamori S; Sakon M; Monden M
Clin Cancer Res; 1999 Dec; 5(12):4005-12. PubMed ID: 10632332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
